GBR 13069 dihydrochloride是一种具有选择性的多巴胺摄取抑制剂（IC50=40~51nM）。
Cas No.:67469-45-8
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
GBR 13069 dihydrochloride is a selective dopamine uptake inhibitor (IC50=40~51nM). GBR 13069 dihydrochloride increases the concentrations of dopamine and norepinephrine in the synaptic cleft by blocking the dopamine transporter (DAT) and norepinephrine transporter (NET), thereby modulating the physiological functions of neural circuits[1-2]. GBR 13069 dihydrochloride can be used for neuroscience research and pharmacological studies in models of dopamine-related neuropsychiatric disorders[3-4].
In vivo, GBR 13069 dihydrochloride (2µM) was co-injected with 6-hydroxydopamine (6-OHDA; 800µM) into the substantia nigra pars compacta (SNpc; 1µl) of rats. GBR 13069 dihydrochloride completely inhibited the 6-OHDA-induced degeneration of nigral dopaminergic neurons and the elevation of intracellular hydrogen peroxide (H2O2) levels in the SNpc[5]. GBR 13069 dihydrochloride (10mg/kg; i.p.) was administered to male white Swiss CD1 mice. GBR 13069 dihydrochloride occupied striatal dopamine uptake sites and significantly increased locomotor activity in the mice[6].
References:
[1] Heikkila RE, Manzino L. Behavioral properties of GBR 12909, GBR 13069 and GBR 13098: specific inhibitors of dopamine uptake. Eur J Pharmacol. 1984 Aug 17;103(3-4):241-8.
[2] Vaugeois JM, Bonnet JJ, Costentin J. In vivo labelling of the neuronal dopamine uptake complex in the mouse striatum by [3H]GBR 12783. Eur J Pharmacol. 1992 Jan 7;210(1):77-84.
[3] Sonsalla PK, Manzino L, Heikkila RE. Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway. J Pharmacol Exp Ther. 1988 Oct;247(1):180-5.
[4] Sonsalla PK, Youngster SK, Kindt MV, et al. Characteristics of 1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the mouse. J Pharmacol Exp Ther. 1987 Sep;242(3):850-7.
[5] Nishio R, Morioka H, Takeuchi A, et al. Intracellular hydrogen peroxide produced by 6-hydroxydopamine is a trigger for nigral dopaminergic degeneration of rats via rapid influx of extracellular Zn2. Neurotoxicology. 2022 Mar;89:1-8.
[6] Vaugeois JM, Bonnet JJ, Duterte-Boucher D, et al. In vivo occupancy of the striatal dopamine uptake complex by various inhibitors does not predict their effects on locomotion. Eur J Pharmacol. 1993 Jan 12;230(2):195-201.
GBR 13069 dihydrochloride是一种具有选择性的多巴胺摄取抑制剂（IC50=40~51nM）。GBR 13069 dihydrochloride通过阻断多巴胺转运体（DAT）和去甲肾上腺素转运体（NET）来增加突触间隙中多巴胺和去甲肾上腺素的浓度，从而调节神经回路的生理功能[1-2]。GBR 13069 dihydrochloride可用于神经科学研究和多巴胺相关神经精神疾病模型的药理研究[3-4]。
在体内，将GBR 13069 dihydrochloride（2μM）与6-羟基多巴胺（6-OHDA；800μM）共同注射到大鼠的黑质致密部（SNpc；1μl）。GBR 13069 dihydrochloride完全抑制了由6-OHDA诱导的黑质多巴胺能神经变性和黑质细胞内过氧化氢（H2O2）水平升高[5]。GBR 13069 dihydrochloride（10mg/kg；腹腔注射）用于处理雄性白色Swiss CD1小鼠。GBR 13069 dihydrochloride能够占据纹状体多巴胺摄取位点并显著增加小鼠的运动活性[6]。
| Animal experiment [1]: | |
Animal models | Male Wistar rats (10-20 weeks of age). |
Preparation Method | 2μM GBR 13069 dihydrochloride was co-injected with 800μM 6-hydroxydopamine (6-OHDA) into the substantia nigra pars compacta (SNpc) of anesthetized rats via a stereotaxically implanted cannula at a rate of 0.2μl/min for 5min. |
Dosage form | 2μM at a rate of 0.2μl/min for 5min; intranigral injection; single injection. |
Applications | Co-injection of GBR 13069 dihydrochloride completely inhibited the 6-OHDA-induced degeneration of nigral dopaminergic neurons and completely inhibited the 6-OHDA-induced elevation of intracellular hydrogen peroxide (H₂O₂) level in the SNpc. |
References: | |
| Cas No. | 67469-45-8 | SDF | |
| 化学名 | 1-(2-(bis(4-fluorophenyl)methoxy)ethyl)-4-cinnamylpiperazine dihydrochloride | ||
| Canonical SMILES | FC1=CC=C(C(OCCN2CCN(CC2)C/C([H])=C([H])/C3=CC=CC=C3)C4=CC=C(F)C=C4)C=C1.Cl.Cl | ||
| 分子式 | C28H30F2N2O.2HCl | 分子量 | 521.48 |
| 溶解度 | Soluble to 5 mM in Water | 储存条件 | Desiccate at RT |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.9176 mL | 9.5881 mL | 19.1762 mL |
| 5 mM | 383.5 μL | 1.9176 mL | 3.8352 mL |
| 10 mM | 191.8 μL | 958.8 μL | 1.9176 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet